Phase 1/2a study of once daily oral BAL101553, a novel tumor checkpoint controller (TCC), in adult patients with advanced solid tumors.

被引：1
|
作者：
Lopez, Juanita Suzanne
Plummer, Elizabeth Ruth
Devlin, Michael-John
Rulach, Robert
Garces, Alvaro Henrique Ingles
Haris, Noor R. Md
Miller, Rowan
Crawford, Donna
D'Arcangelo, Manolo
Aversa, Caterina
Hannah, Alison L.
Anderson, Stephanie
Engelhardt, Marc Frederick
Kaindl, Thomas
Larger, Patrice
Bachmann, Felix
Lane, Heidi A.
McKernan, Phil
Evans, T. R. Jeffry
Kristeleit, Rebecca Sophie
机构：
[1] Royal Marsden Hosp, Sutton, Surrey, England
[2] Inst Canc Res, Sutton, Surrey, England
[3] Freeman Rd Hosp, Northern Ctr Canc Care, Newcastle Upon Tyne, Tyne & Wear, England
[4] Univ Coll London Hosp, London, England
[5] Beatson West Scotland Canc Ctr, Glasgow, Lanark, Scotland
[6] UCL, Canc Inst, London, England
[7] Oncol Clin Trial Consulting, Sebastopol, CA USA
[8] Basilea Pharmaceut Int Ltd, Basel, Switzerland
[9] Univ Glasgow, Glasgow, Lanark, Scotland
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2018年 / 36卷 / 15期
关键词：
D O I：
10.1200/JCO.2018.36.15_suppl.2530
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2530
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Lisavanbulin (BAL101553), a novel, oral microtubule destabilizer plus radiation in patients with newly diagnosed, MGMT promoter unmethylated glioblastoma: A phase 1 Adult Brain Tumor Consortium study (ABTC1601)
    Holdhoff, Matthias
    Ye, Xiaobu
    Strowd, Roy E.
    Nabors, Louis B.
    Walbert, Tobias
    Lieberman, Frank S.
    Bagley, Stephen Joseph
    Fiveash, John B.
    Fisher, Joy D.
    Desideri, Serena
    Engelhardt, Marc
    Kaindl, Thomas
    Lane, Heidi A.
    Grossman, Stuart A.
    Kleinberg, Lawrence
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [22] Phase I safety and pharmacokinetic study of oral TAS-102 once daily for fourteen days in patients with solid tumors.
    Hoff, PM
    Bogaard, K
    Lassere, Y
    Aguayo, A
    Hayakawa, T
    Abbruzzese, JL
    CLINICAL CANCER RESEARCH, 2000, 6 : 4552S - 4553S
  • [23] Phase 1 and phase 2a, first-in-human (FIH) study, of DRP-104, a broad glutamine antagonist, in adult patients with advanced solid tumors.
    Johnson, Melissa Lynne
    Doroshow, Deborah Blythe
    Seiwert, Tanguy Y.
    Gibson, Michael K.
    Velcheti, Vamsidhar
    Lisberg, Aaron Elliott
    Patel, Shetal Arvind
    Scheffler, Matthias
    Lafleur, Francois
    Dugan, Margaret Han
    Sharma, Sunil
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [24] Phase I safety and tolerability of once daily oral afatinib (A) in combination with docetaxel (D) in patients (pts) with relapsed or refractory advanced solid tumors.
    Senellart, Helene
    Bennouna, Jaafar
    Isambert, Nicolas
    De-Montserrat, Helene
    Squiban, Patrick J.
    Tschoepe, Inga
    Delord, Jean-Pierre
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [25] A phase 1/2 study of intermittent, high dose sunitinib in patients with advanced solid tumors.
    Rovithi, Maria
    Labots, Marlette
    Richard
    Honeywell
    Ten Tije, Albert J.
    Ruijter, Rita
    Skardhamar, Mikkjal
    Peters, Godefridus J.
    Voortman, Jens
    Verheul, Henk M. W.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [26] Oral topotecan given once or twice daily for ten days: A Phase I pharmacology study in adult patients with solid tumors
    Gerrits, GJH
    Burris, H
    Schellens, JHM
    Eckardt, JR
    Planting, AST
    van der Burg, MEL
    Rodriguez, GI
    Loos, WJ
    van Beurden, V
    Hudson, I
    Fields, S
    Von Hoff, DD
    Verweij, J
    CLINICAL CANCER RESEARCH, 1998, 4 (05) : 1153 - 1158
  • [27] A phase I trial of the novel oral taxane BMS-275183 in patients with advanced solid tumors.
    Broker, LE
    De Vos, FY
    Gall, H
    Gietema, JA
    Voi, M
    Cohen, MB
    De Vries, EG
    Giaccone, G
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 134S - 134S
  • [28] Phase I pharmacokinetic (PK) study of daily imatinib in combination with docetaxel for patients with advanced solid tumors.
    Chatta, GS
    Fakih, M
    Ramalingam, S
    Belani, CP
    Ramanathan, RK
    Zamboni, N
    Friedland, D
    Lis, D
    Tutchko, S
    Egorin, M
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 138S - 138S
  • [29] Phase I study of CFI-402257, an oral TTK inhibitor, in patients with advanced solid tumors.
    Cescon, David W.
    Hansen, Aaron Richard
    Razak, Albiruni Ryan Abdul
    Stayner, Lee-Anne
    Hilton, John Frederick
    Renouf, Daniel John
    Denny, Trisha
    Fletcher, Graham
    Mak, Tak W.
    Bray, Mark R.
    Bedard, Philippe L.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [30] The potential utility of end-binding protein 1 (EB1) as response-predictive biomarker for lisavanbulin: A phase 2 study of lisavanbulin (BAL101553) in adult patients with recurrent glioblastoma.
    Tiu, Crescens Diane
    Derby, Sarah
    Haris, Noor Md
    Welsh, Liam
    Stansfeld, Anna
    Hundsberger, Thomas
    Roth, Patrick
    Konig, Fatima
    Eisner, Joel Robert
    Kleinschmidt, Malte
    Anderson, Stephanie
    Bachmann, Felix
    Lane, Heidi A.
    Engelhardt, Marc
    Kaindl, Thomas
    Litherland, Karine
    Stan, Alexandru C.
    Evans, T. R. Jeffry
    Plummer, Elizabeth Ruth
    Lopez, Juanita Suzanne
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
12345